Trial Profile
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Ataluren (Primary)
- Indications Cystic fibrosis
- Focus Registrational; Therapeutic Use
- Acronyms ACT CF
- Sponsors PTC Therapeutics
- 29 Mar 2017 This trial has been suspended in Germany, according to European Clinical Trials Database.
- 23 Mar 2017 This trial has been Discontinued in Germany, according to European Clinical Trials Database.
- 04 Mar 2017 This trial has been completed in Greece (end date: 2 Nov 2016).